BioCryst designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and inflammatory diseases.
BioCryst uses state-of-the-art structure-guided drug design, which incorporates multiple scientific disciplines including biology, crystallography, medicinal chemistry and computer modeling, in order to most efficiently develop new therapeutic candidates. In December 2014, RAPIVAB® was approved by the FDA, the first U.S. approval for a BioCryst discovered drug.
BioCryst's current pipeline consists of the following development programs:
Oral inhibitors of plasma kallikrein for hereditary angioedema;
- BCX4161, BCX7353 and other 2nd generation candidates
- BCX4430 a broad spectrum antiviral for development as a medical countermeasure against hemorrhagic fevers
Latest jobs from BioCryst Pharmaceuticals,Inc.